NCT02663297View on ClinicalTrials.gov

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 7, 2016

Primary Completion Date

January 15, 2021

Study Completion Date

January 31, 2037

Conditions
Hodgkin DiseaseLymphomaLymphoma, Non-HodgkinImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic Type
Interventions
DRUG

ATLCAR.CD30 cells

"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)"

Trial Locations (2)

27157

Wake Forest University, Winston-Salem

27599

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER